Destiny, SporeGen collaborate on COVID-19 prevention spray
Development of SPOR-COV is supported by a grant from Innovate UK
Read More
Tag: destiny pharma
Destiny Pharma’s novel antibiotic asset clears safety review
Independent Data Monitoring Committee recommended continuing Phase IIb study
Read More
Destiny Pharma to get £1.6M grant for AMR
Destiny Pharma has been awarded a significant new grant funding up to £1.6 million, under the new UK-China antimicrobial resistance (AMR) programme.
Read More
Destiny Pharma listed on London Stock Exchange
Brighton, UK-based Destiny Pharma has been successfully listed shares on London Stock Exchange with a market capitalisation of £65.4 million, marking the second biotech company to float this year in the UK.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
